



Company Focus

30 October 2007 | 8 pages

Moser Baer India (MOSR.BO)

Estimate change of

Sell: Weak Q2FY08; First Quarter of PV Revenues

- Weak 2QFY08 results Moser Baer reported revenue of Rs4.48b (down 11% yoy). EBITDA at Rs1.14b was down ~15% yoy while EBIT at Rs80m was down ~82% yoy. Net profit of Rs33m was down ~87% yoy. EBITDA was lower than our expectation of Rs1.17b despite a positive impact of one-time adjustment of Rs141m (refund of countervailing duty).
- First quarter for Solar (PV) business Moser Baer recorded sales of US\$12m for its Silicon based solar cells - billed volume of 5-5.5 MW. In 2Q08, this business was at breakeven at EBITDA level. Moser expects breakeven at net level in Q3. The company re-affirmed its plan of 80MW capacity by FY08 end and mentioned that Silicon based solar cell plant was working at 90%+ yield.
- Home entertainment business Management reiterated its guidance of US\$60m revenue in FY08. During the quarter, the company acquired more titles taking the content to 9,500 titles (over 45% of mainstream cinema in India). Also, distribution network is in place and is expanding its footprint.
- Optical media business outlook Despite a traditionally strong winter season ahead, there is the possibility of a short-term negative impact on pricing due to cancellation of licenses of a few manufacturers by Philips – as per Moser Baer.
- Cutting estimates; Maintain Sell (3H) We have cut our estimates for FY08 by ~16% on account of a weaker than expected Q2; broadly maintain FY09 and FY10 estimates. Sales growth should accelerate as the PV business starts contributing meaningfully; maintain Sell (3H) on limited upside and high risk.

Statistical Abstract								
Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield	
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)	
2006A	-65	-0.39	-110.8	nm	2.4	-0.3	0.2	
2007A	788	4.68	na	60.9	2.3	3.9	0.4	
2008E	1,734	9.42	101.2	30.2	2.4	8.6	0.4	
2009E	4,327	23.50	149.5	12.1	2.0	19.8	0.4	
2010E	6,675	36.25	54.3	7.9	1.6	24.6	0.4	

See Appendix A-1 for Analyst Certification and important disclosures.

Source: Powered by dataCentral

Sell/High Risk	3Н
Price (30 Oct 07)	Rs284.85
Target price	Rs345.00
Expected share price return	21.1%
Expected dividend yield	0.4%
Expected total return	21.5%
Market Cap	Rs47,647M
	US\$1,211M

Price Per	forman	ce (RIC: MO	SR.BO, BB	: MBI IN)
INR				
300			~	M
250	٨	/		V
200		M		
150	V			
	29 Dec	30 Mar	29 Jun	28 Sep

Surendra Goyal, CFA¹				
+91-22-6631-9870				
surendra.goyal@citi.com				
Hitesh Shah, CFA ¹				
+91-22-6631-9872				
hitesh.b.shah@citi.com				
Vishal Agarwal ¹				
vishal1.agarwal@citi.com				

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. ¹Citigroup Global Markets India Private Limited

BVPS 118.90 122.29 118.16 142.86 181.58 DPS 0.67 1.00 1.00 1.00 1.00 1.00 Profit & Loss (RSM)	Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
EVERDIDA adjusted (x)	Valuation Ratios					
P/BV (x)	P/E adjusted (x)	nm	60.9	30.2	12.1	
Dividend yield (%) 0.2 0.4 0.4 0.4 0.4						
Per Share Data (Rs) Co.39 4.68 9.42 23.50 36.25 BVPS 118.90 122.29 118.16 142.86 181.58 DPS 0.67 1.00 1.00 1.00 1.00 Profit & Loss (RsM) Net sales 16.641 19.840 24.388 38.439 51.083 Operating expenses -16.378 -18.460 -21.966 -32.911 -42.921 EBIT 263 1.380 2.422 5.528 8.161 Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 -0 0 -744 Net interest expense -377 -102 -193 -481 -742 EBIT 283 1.380 2.422 5.528 8.161 Net interest expense -377 -497 -495 -720 -744 Apace 27 -0 0 0 0 0 0 <td< td=""><td>• •</td><td></td><td></td><td></td><td></td><td></td></td<>	• •					
EPS adjusted -0.39 4.68 9.42 23.50 36.25 EPS reported -0.39 4.68 9.42 23.50 36.25 EPS reported -0.39 4.68 9.42 23.50 36.25 DPS 0.67 1.00 1.00 1.00 1.00 Profit & Loss (RsM) No.67 1.00 1.00 1.00 1.00 Profit & Loss (RsM) No.68 16.641 19.840 24.388 38.439 51.083 Operating expenses -16.378 -18.460 -21.966 -32.911 -42.921 Bett interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0 0 0 Pre-tax profit -72 890 1.927 4.807 7.417 Tax 7 -102 -193 -481 -742 Extraord./Min.Int./Pref.div. 0 0 0 0 0 Extraord./Min.Int./Pr		0.2	0.4	0.4	0.4	0.4
EPS reported -0.39 4.68 9.42 23.50 36.25 BVPS 118.90 122.29 118.16 142.86 181.58 DPS 0.67 1.00 1.00 1.00 1.00 Profit & Loss (RsM) Net sales 16,641 19,840 24,388 38,439 51,083 Operating expenses -16,378 -18,460 -21,966 32,911 -42,921 EBIT 283 1,380 2,422 5,528 8,161 Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0 0 0 0 Pre-tax profit -72 890 1,927 4,807 7,417 Tax 7 -102 -193 -481 -742 Extraord/Min.Int/Pref.div. 0 0 0 0 0 0 Adjusted earnings -65 788 1,734 4,327 6,675 Adjust						
BVPS 118.90 122.29 118.16 142.86 181.58 DPS 0.67 1.00 1.00 1.00 1.00 1.00 Profit & Loss (RsM)						
DPS 0.67 1.00 1.00 1.00 1.00 Profit & Loss (RSM) Net sales 16,641 19,840 24,388 38,439 51,083 Operating expenses -16,378 -18,460 -21,966 -32,911 -42,921 EBIT 263 1,380 2,422 5,528 8,161 Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0						
Profit & Loss (RsM)						
Net sales 16,641 19,840 24,388 38,439 51,083 Operating expenses -16,378 -18,460 -21,966 -32,911 -42,921 EBIT 263 1,380 2,422 5,528 8,161 Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0 0 0 0 0 0 0 0 0		0.67	1.00	1.00	1.00	1.00
Operating expenses -16,378 -18,460 -21,966 -32,911 -42,921 EBIT 263 1,380 2,422 5,528 8,161 Non-operating/exceptionals 42 7 -0 0 0 Pre-tax profit -72 890 1,927 4,807 7,417 Tax 7 -102 -193 -481 -742 Extraord/Min.Int/Pref.div. 0 0 0 0 0 0 Reported net income -65 788 1,734 4,327 6,675 Adjusted earnings -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Frowth Rates (%) Sales 30.0 19.2 22.9 57.6 32.9 Sales 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBIT adjusted -9.3						
BIT 263 1,380 2,422 5,528 8,161 Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0 0 0 Pre-tax profit -72 890 1,927 4,807 7,417 Tax 7 -102 -193 -481 -742 Extraord_Min.Int/Pref.div. 0 0 0 0 0 Reported net income -65 788 1,734 4,327 6,675 Adjusted earnings -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) Sales 30,0 19,2 22,9 57,6 32,9 EBIT adjusted -32,2 425,1 75,5 128,2 47,6 EBITDA adjusted -32,2 425,1 75,5 128,2 47,6 EBITDA dajusted -32,2 425,1 75,5 128,2 47,6 EBITDA dajusted -32,2 425,1 75,5 128,2 47,6 EBITDA gainsted -31,0 8 mm 101,2 149,5 54,3 EPS adjusted -110,8 nm 101,2 149,5 54,3 EPS adjusted -3,5 6,614 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Acquisitions/disposals 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 Dividends paid -127 -196 -193 -193 -193 Borrowings 348 1,948 6,075 3,200 0 0 Dividends paid -127 -196 -193 -193 -193 -193 Change in cash -1,693 -2,03 -1,679 -2,137 Balance Sheet (RSM) -1,694 -1,695						
Net interest expense -377 -497 -495 -720 -744 Non-operating/exceptionals 42 7 0 0 0 Pre-tax profit -72 890 1,927 4,807 7,417 Tax 7 -102 -193 -481 -742 Extraord./Min.Int./Pref.div. 0 0 0 0 0 Reported net income -65 788 1,734 4,327 6,675 Adjusted earnings -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) Sales 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted -6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) Operating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Net working capital -2,508 685 -1,425 -3,927 -3,533 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 0 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 0 0 0		,				
Non-operating/exceptionals						
Pre-tax profit -72 890 1,927 4,807 7,417 Tax 7 -102 -193 -481 -742 Extraord./Min.Int./Pref.div. 0 0 0 0 0 Reported net income -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted -32.2 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) 0 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) 0 958 5,641 4,886 5,750 9,112 Depreciating cash flow -1,933						
Tax			-	-	-	
Extraord/Min.Int./Pref.div. 0 0 0 0 0 0 Reported net income -65 788 1,734 4,327 6,675 Adjusted earnings -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) Sales 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted 6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3	-				-	,
Reported net income -65 788 1,734 4,327 6,675 Adjusted earnings -65 788 1,734 4,327 6,675 Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) Sales 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted 6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,80						
Adjusted earnings				-		
Adjusted EBITDA 3,430 4,963 6,504 10,157 13,387 Growth Rates (%) 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) Operating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,800 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Borrowings 348 1,948 6,075 3,2						
Sales 30.0 19.2 22.9 57.6 32.9 EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted 6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) Operating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075		3,430	4,963	6,504		
EBIT adjusted -32.2 425.1 75.5 128.2 47.6 EBITDA adjusted 6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM)	Growth Rates (%)					
EBITDA adjusted 6.9 44.7 31.1 56.2 31.8 EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) Upperating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 37	Sales	30.0	19.2	22.9	57.6	32.9
EPS adjusted -110.8 nm 101.2 149.5 54.3 Cash Flow (RsM) Operating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43	EBIT adjusted	-32.2	425.1	75.5	128.2	47.6
Cash Flow (RsM) 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) -2,900 2,697 1,018 1,255 1,631			44.7			31.8
Operating cash flow 958 5,641 4,886 5,750 9,112 Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM)	EPS adjusted	-110.8	nm	101.2	149.5	54.3
Depreciation/amortization 3,168 3,582 4,082 4,629 5,226 Net working capital -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RSM)	Cash Flow (RsM)					
Net working capital newsting cash flow -2,508 685 -1,425 -3,927 -3,533 Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 19,265 28,811 34,449		958	5,641			
Investing cash flow -1,933 -6,335 -8,920 -6,800 -6,600 Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) 59,883 68,895 68,895 68,895 68,895 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 <td></td> <td>,</td> <td>,</td> <td></td> <td></td> <td></td>		,	,			
Capital expenditure -4,031 -6,598 -9,720 -7,800 -7,800 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 1						
Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Financing cash flow -718 491 2,355 1,287 -2,137 Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927						
Borrowings 348 1,948 6,075 3,200 0 Dividends paid -127 -196 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted						
Dividends paid -127 -196 -193 -193 -193 -193 Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26	_					_
Change in cash -1,693 -203 -1,679 237 375 Balance Sheet (RsM) Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjust	•			,		
Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0						375
Total assets 39,094 43,559 49,739 59,883 68,895 Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0	Balance Sheet (RsM)					
Cash & cash equivalent 2,900 2,697 1,018 1,255 1,631 Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0		39.094	43.559	49.739	59.883	68.895
Accounts receivable 3,799 3,342 4,343 6,845 9,097 Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0						
Net fixed assets 25,845 28,811 34,449 37,620 40,194 Total liabilities 19,206 23,076 29,946 35,956 38,485 Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0		,				
Accounts payable 2,651 4,485 5,280 8,090 10,619 Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0						
Total Debt 16,555 18,502 24,577 27,777 27,777 Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0	Total liabilities	19,206	23,076	29,946	35,956	38,485
Shareholders' funds 19,888 20,483 19,793 23,927 30,410 Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0	Accounts payable					10,619
Profitability/Solvency Ratios (%) EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0			,			
EBITDA margin adjusted 20.6 25.0 26.7 26.4 26.2 ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0	Shareholders' funds	19,888	20,483	19,793	23,927	30,410
ROE adjusted -0.3 3.9 8.6 19.8 24.6 ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0	Profitability/Solvency Ratios (%)					
ROIC adjusted 0.9 3.7 5.7 11.0 14.1 Net debt to equity 68.7 77.2 119.0 110.8 86.0	EBITDA margin adjusted		25.0	26.7		
Net debt to equity 68.7 77.2 119.0 110.8 86.0						
						14.1
iotal debt to capital 45.4 47.5 55.4 53.7 47.7						
	ioral dept to capital	45.4	4/.5	55.4	53./	4/./

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Rs m	2007	2008	Change
Net Sales	5,009	4,478	-10.6%
CoGS	2,456	1,986	-19.1%
Staff Cost	350	473	35.4%
Other expenditure	872	882	1.1%
Total expenditure	3,678	3,342	-9.1%
EBITDA	1,331	1,136	-14.6%
EBITDA margin (%)	26.6%	25.4%	-119bp
Depreciation	891	1,056	18.6%
EBIT	440	80	-81.8%
EBIT margin (%)	8.8%	1.8%	-699bp
Other Income	124	425	243.3%
Interest	300	465	54.6%
Profit before Tax	263	41	-84.5%
Tax	3	15	366.7%
Other prov/Prior period item	0	-7	NM

260

33

-87.4%

Source: Company Reports

Profit after Tax

	•			
Figure	"	Earnings	revision	table

FYE	Net Profit	EPS	%	DPS
31 Mar	(RsM)	(Rs)	chg	(Rs)
2008E	1,734	9.42	-16.3	1.00
Prev	2,073	11.26		1.00
2009E	4,327	23.50	-1.2	1.00
Prev	4,381	23.79		1.00
2010E	6,675	36.25	-0.5	1.00
Prev	6,707	36.42		1.00

Source: Citi Investment Research

Moser Baer India

Company description

Moser Baer India is a Delhi-based company with interests in optical media, home entertainment and the solar industry. The company is the world's second-largest manufacturer of optical storage media and has a significant global market share - with most of the world's 10 largest OEMs among its customers. Photovoltaic Cell & Module (PV) is a new business for which Moser Baer has aggressive ramp up plans (~400-500MW in the next 3-4 years). Moser has also forayed into home entertainment with an eye on increased penetration in the CD/DVD market in India - this will help the ASP for its optical discs. Also, it is forward integration for Moser's optical media business.

Investment strategy

We have a Sell/High Risk rating on the Moser Baer stock. Despite having a significant market share in the optical media business, the company has suffered a notable reduction in profitability on account of sharp price escalations in the key raw material - polycarbonate (PC). We expect this business to grow 15-20% yoy in volume terms, with profitability improving as PC prices ease. Photovoltaic Cell & Module (PV) is a new business for which

Moser Baer has aggressive ramp up plans (~400-500MW in the next 3-4 years). Various government incentives should continue to drive demand globally, but pricing and profitability are difficult to forecast, with margins likely to be under pressure from increases in solar-grade silicon prices, competition from Chinese/European players, and low entry barriers (particularly for cells and modules). Home entertainment is still an early-stage business, which we value at 1x Moser's investment.

Valuation

Our target price for Moser Baer of Rs345 is derived from a sum-of-parts (SoP) methodology in which we value the optical media (incl. home entertainment) and Photovoltaic (PV) businesses at respective EVs per share of Rs235 and Rs214, before adjusting for net debt of Rs113 per share.

We value the optical media business at 1.0x EV/Capital Employed on FY09E - over the past three years (prior to its venture in the PV business), Moser Baer has traded at an average EV/Capital Employed of 1.1x (in a 0.8-1.4x range). We believe 1.0x is a fair multiple as Moser's current ROIC is below its cost of capital.

We value the PV business at 15x FY09E EV/EBITDA - this is at a $\sim 10\%$ discount to the average CY08E EV/EBITDA multiple for cell and module makers. We believe this discount is fair given Moser's PV business is still in early stages and hence there are some execution risks.

Risks

We rate Moser Baer shares High Risk based on our quantitative risk-rating system, which tracks 260-day historical share price volatility. We believe this is justified given the risk inherent in the optical media business and given the early stages of the company's PV and home entertainment businesses.

Some of the upside risk to the stock price are: (1) Improvements in the ASP and margins of optical media discs - CD/DVDs, (2) Improvement in margins for the solar industry, (3) Sale of a stake in the PV business to private-equity interests at a higher price than our assumed valuation (4) Higher crude oil prices, leading to enhanced interest in solar cell and module makers.

Appendix A-1

Analyst Certification

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

IMPORTANT DISCLOSURES



Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Moser Baer India. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Moser Baer India.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Moser Baer India.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Moser Baer India in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Moser Baer India.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Moser Baer India.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Moser Baer India.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from Moser Baer India.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution					
Data current as of 30 September 2007	Buy	Hold	Sell		
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%		
% of companies in each rating category that are investment banking clients	53%	55%	42%		

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

30 October 2007

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underper

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 30 October 2007 03:50 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private

Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11° andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand, The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or

Moser Baer India (MOSR.BO)

30 October 2007

contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST